Amplitude Ventures

Canadian start-up’s self-assembling scaffold creates high avidity antibodies against challenging targets

Plus fundings around the globe for Eg 427, Atrandi and Reverb

Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G

Plus: Forbion’s new sustainability fund, and rounds for Elion, ashibio, NephroDI and Ability

Plus: Adcendo’s series A is again Denmark’s largest; VCs and foundations back Lucy

Vancouver-based Reverb is making bispecific antibodies to nab cytokines and deliver them to a desired cell or tissue

Backed with $145M since 2020, the biotech has a Phase IIa molecule for atopic dermatitis, plus at least two preclinical programs

Plus: Medicare to cover Leqembi, if approved; Sangamo restructuring; and updates from Roche, GSK, Seres and more

Backed with $142M, start-up aims to thread a PK needle for antibody-based radiotherapies, avoiding kidney and bone marrow issues

A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology